|1.||Hortobagyi, Gabriel N: 29 articles (01/2015 - 02/2002)|
|2.||Perez, Edith A: 19 articles (11/2015 - 01/2003)|
|3.||von Minckwitz, Gunter: 18 articles (07/2015 - 08/2004)|
|4.||Loibl, Sibylle: 17 articles (07/2015 - 01/2008)|
|5.||du Bois, Andreas: 15 articles (05/2015 - 08/2004)|
|6.||Valero, Vicente: 14 articles (12/2015 - 03/2003)|
|7.||Sood, Anil K: 14 articles (04/2015 - 12/2005)|
|8.||Coleman, Robert L: 14 articles (04/2015 - 01/2002)|
|9.||Katsumata, Noriyuki: 13 articles (07/2015 - 08/2002)|
|10.||Huober, Jens: 13 articles (07/2015 - 04/2007)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2015 - "The most effective regimen for taxane- and anthracycline-refractory triple-negative breast cancer (TNBC) has not yet been established. "
08/04/2014 - "Cellax also exhibited significantly increased efficacy compared with that of DTX in a taxane-resistant breast tumor model. "
06/01/2015 - "The addition of a taxane to an anthracycline-based regimen in the adjuvant setting has improved the disease-free survival and overall survival in patients with early breast cancer. "
11/01/2009 - "S-1 administrations can be an effective treatment for advanced breast cancer resistant to anthracycline and taxane when considering a satisfactory QOL of patients."
04/01/2008 - "These limitations have led to the development of new taxane derivatives with fewer side effects, superior pharmacological properties, and improved anticancer activity to maximize the induced benefits for breast cancer patients. "
03/01/2005 - "Therefore, it is important to develop new taxane anticancer agents with fewer side effects, superior pharmacological properties, and improved activity against drug-resistant human cancers. "
06/01/2011 - "The tumor modeling studies clearly showed that EGCG plus taxane injected intraperitoneally (i.p.) induced a significant increase in apoptosis rates (TUNEL assays) and eliminated preexisting tumors generated from PC-3ML cells implanted i.p., increasing disease-free survival rates to greater than 90%. "
10/13/2015 - "Furthermore, combination of A3 and taxane led to significant reduction of implanted tumor size without increase in hematological, hepatic or renal toxicity. "
08/01/2012 - "In the taxane-resistant HeyA8-MDR model, significant reduction in tumor weight and nodule counts was noted in the metronomic groups whereas the response of the MTD group did not achieve significance. "
06/01/2009 - "Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
06/01/2011 - "To study the role of survivin and its splice variants in taxane-resistant ovarian cancer. "
06/01/2011 - "While PPX is active in ovarian cancer, it is unclear at present whether it offers significant benefit in terms of its side-effect profile or outcomes over a standard taxane-based regimen as first-line therapy, or what role it will have in maintenance therapy as studies are ongoing."
08/01/2006 - "This trial is also designed to address some of the questions regarding the role of a novel taxane in maintenance therapy in ovarian cancer."
10/29/1998 - "Although additional studies are needed to define the molecular basis of the TX-LND interaction, our results suggest that LND can positively modulate the antitumor activity of TX in ovarian cancer cells and indicate that the energolytic is potentially useful in combination therapy including the taxane in ovarian cancer patients."
02/01/2015 - "Differential platelet levels affect response to taxane-based therapy in ovarian cancer."
|4.||Prostatic Neoplasms (Prostate Cancer)
08/01/2012 - "Because a plateau has been reached in the development of taxane-based treatments for prostate cancer, this study was undertaken to evaluate the relative efficacy of targeting telomeres and microtubules in taxane-sensitive, taxane-resistant, androgen-sensitive, and androgen-insensitive prostate cancer cells. "
06/01/2011 - "Taken together, these data demonstrate for the first time that EGCG in combination with taxane may provide a novel therapeutic treatment of advanced prostate cancer."
01/01/2009 - "Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer."
09/01/2011 - "In this study, the antitumor activity of PSMA ADC was evaluated against a panel of prostate cancer cell lines in vitro and in a novel in vivo model of taxane-refractory human prostate cancer. "
05/01/2008 - "For advanced prostate cancer, the first prospective trial defining taxane-resistant prostate cancer is described. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2008 - "A phase I/II study was performed to assess the efficacy and toxicity of a new oral taxane in patients with recurrent, advanced Non-small Cell Lung Cancer. "
07/01/2008 - "Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer."
01/01/2014 - "Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer."
01/01/2010 - "Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens."
03/01/2009 - "Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer."
|7.||ixabepilone (BMS 247550)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)